After finding no safety concerns in Part A of the DEVOTE trial, which is testing higher doses of Spinraza (nusinersen) among people of all ages with spinal muscular atrophy (SMA), investigators are now screening patients for the study’s pivotal Part B, according to Biogen, the therapy’s maker. Part B, which dosed its first patient last November, is aiming to prove the safety and efficacy of the therapy’s higher dose. Biogen announced in a press release that…

You must be logged in to read/download the full post.